Abbvie (ABBV +1.05%), the Abbott spinoff that made its New York Stock Exchange debut at the start of the year, recently announced that its chief scientific officer will retire in the coming months. A new CSO has not yet been revealed, but is this something that investors need to watch? Can this appointment offer clues as to AbbVie's future strategy, much as a recent shake-up at Merck (MRK +1.65%) did? Health-care analyst Max Macaluso discusses this story in the following video.
AbbVie Investors, Watch This Management Change
By Max Macaluso – May 18, 2013 at 6:30PM
NYSE: ABBV
AbbVie
Market Cap
$387B
Today's Change
(1.05%) $2.27
Current Price
$219.04
Price as of November 6, 2025 at 4:00 PM ET
What strategy will the company's new chief scientific officer pursue?
About the Author
Max is the Technology, Biopharma & Health Care Bureau Chief at Fool.com. Prior to joining the Fool, he completed a PhD in chemistry at the University of Cambridge and an MBA at the College des Ingenieurs.
Follow @TMFMassimo